(Q35814104)

English

Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir

scientific article published on May 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

S Safrin

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

T Schacker

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

J Delehanty

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

E Hill

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

L Corey

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

1 May 1993

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

37

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

975-979

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Treatment of resistant herpes simplex virus with continuous-infusion acyclovir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

The Pathogenicity of Ribonucleotide Reductase-Null Mutants of Herpes Simplex Virus Type 1 in Mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone (348U87).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

27 July 2018

A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=187867

24 September 2018

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8390815

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/8390815

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/8390815

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.37.5.975

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35814104&oldid=2175261264"